Resource Logo
Reuters New Media

FDA says Merck's HIV drug gets generic threat




 

Reuters NewMedia - January 10, 2012

Health regulators said they have received applications from generic drugmakers to make copycat versions of Merck & Co's HIV drug Isentress, GlaxoSmithKline's HIV drug Epivir and Bayer AG's birth control pill Beyaz.

However, the U.S. Food and Drug Administration did not disclose the names of the generic drug applicants.

Isentress was first approved in 2007 for use in adult patients. Last month, the FDA expanded the label on the drug for use in children and adolescents.

Merck shares were trading almost flat at $38.58 on Tuesday on the New York Stock Exchange.

(Reporting by Anand Basu in Bangalore; Editing by Supriya Kurane)



 


Copyright © 2012 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in January 10, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.